NUS Chemists Pioneer Frustrated Lewis Pair for Dual Atom Insertion in Bioactive Molecule Synthesis

The NUS Breakthrough in Frustrated Lewis Pair Chemistry

Researchers at the National University of Singapore (NUS) have achieved a significant milestone in organic synthesis with a novel boron-catalyzed method that leverages frustrated Lewis pair (FLP) activation for heteronuclear dual-atom insertion into oxetanes. This innovation, detailed in a recent Nature Synthesis publication, transforms simple, strained oxetane rings into complex scaffolds essential for bioactive molecules used in pharmaceuticals and agrochemicals.

Oxetanes, four-membered cyclic ethers known for their ring strain, are abundant and inexpensive but challenging to functionalize selectively. The NUS team's approach addresses this by enabling the simultaneous insertion of one nitrogen (N) and one carbon (C) atom from diverse sources, yielding 1,3-amino alcohol derivatives—a motif prevalent in many therapeutic agents. This step-economical process promises to streamline drug discovery pipelines, reducing synthetic steps and costs.

Demystifying Frustrated Lewis Pairs: A Primer

Frustrated Lewis pairs (FLPs) represent a paradigm shift in main-group chemistry. Discovered around 2006 by Douglas Stephan's group, FLPs consist of a Lewis acid (electron-pair acceptor, here a bulky boron compound) and a Lewis base (electron-pair donor) sterically hindered from forming a traditional dative bond. This 'frustration' preserves their individual reactivities, allowing cooperative activation of inert small molecules like hydrogen gas or, in this case, strained rings.

In traditional Lewis acid-base chemistry, the pair forms an adduct, quenching reactivity. FLPs circumvent this, mimicking transition-metal catalysis with earth-abundant elements. At NUS, Assoc Prof Koh Ming Joo's group harnessed a boron-based FLP to polarize the oxetane C-O bond, facilitating nucleophilic attack and ring-opening with unprecedented selectivity.

Oxetanes in Modern Drug Design

Oxetanes serve as bioisosteres—structural mimics—of carbonyl groups or larger rings, enhancing metabolic stability and solubility in drugs. Examples include the cholesterol-lowering Atorvastatin (Lipitor) and anti-cancer agents. However, their high ring strain (109 kJ/mol) makes controlled functionalization difficult, often leading to polymerization or over-reaction.

The NUS method introduces heteroatoms precisely at the 2,4-positions of the opened oxetane, generating trans-1,3-amino alcohols. These scaffolds appear in beta-blockers, kinase inhibitors, and natural products like sphingosine-1-phosphate receptor modulators.

Step-by-Step: The Dual-Atom Insertion Mechanism

The reaction unfolds in a metal-free environment:

• Step 1: Bulky borane (e.g., B(C₆F₅)₃) coordinates to oxetane oxygen, weakening the C-O bond via FLP activation.
• Step 2: Nitrogen nucleophile (e.g., from azides or amines) attacks the activated carbon, initiating ring-opening.
• Step 3: Carbon source (e.g., isonitriles) inserts, forming the dual-atom chain with boron stabilization.
• Step 4: Protonolysis releases the product and regenerates catalyst.

The Team Behind the Innovation

Led by Associate Professor Koh Ming Joo, the team includes PhD students Ying-Qi Zhang and Shuo-Han Li from NUS Department of Chemistry. Prof Koh, who joined NUS in 2017, specializes in main-group catalysis and C-H activation, with prior experience at Harvard and ETH Zurich. His lab's focus on sustainable synthesis aligns with Singapore's green chemistry goals.

"This FLP strategy not only upgrades oxetanes but opens new avenues for late-stage diversification of bioactive leads," says Prof Koh.

Prestige of Publication in Nature Synthesis

The work appeared in Nature Synthesis on March 12, 2026 (DOI: 10.1038/s44160-026-01031-6), underscoring its novelty. Read the full paper here. Nature Synthesis, launched in 2021, spotlights transformative synthetic methods, placing NUS alongside global leaders like MIT and Max Planck.

Revolutionizing Bioactive Molecule Synthesis

Traditional routes to 1,3-amino alcohols involve multi-step sequences with protecting groups and chromatography. The NUS method is direct, scalable (gram-scale demos), and tolerant of functional groups, ideal for diversity-oriented synthesis (DOS). Applications span kinase inhibitors (e.g., for cancer), antivirals, and neurotransmitters modulators.

In pharma, this could accelerate hit-to-lead optimization, where rapid scaffold modification is key. Singapore's A*STAR and pharma hubs like Pfizer Singapore stand to benefit.

NUS Chemistry: Singapore's Research Powerhouse

NUS Department of Chemistry ranks top 10 globally (QS 2026), with strengths in catalysis and green synthesis. Funded by NRF's RIE2025 ($25B), it hosts 50+ faculty pioneering FLP and beyond. Recent feats include AI-driven retrosynthesis and CRISPR therapeutics. Explore NUS Chemistry research.

Singapore's Higher Education and Innovation Drive

Singapore invests heavily in STEM, with NUS/NTU leading. The Research, Innovation and Enterprise 2025 plan allocates $25B, fostering pharma R&D (GDP contribution 5%). Initiatives like SGInnovate link academia-industry, creating 20K research jobs. This FLP advance exemplifies Singapore's shift to high-value manufacturing.

Future Outlook and Challenges

Next steps include asymmetric variants for chiral drugs and continuous-flow scaling. Challenges: expanding nucleophile scope and mechanistic deep-dive via computation. Prof Koh's group eyes industrial partnerships.

• Potential: 50% reduction in synthesis steps for APIs.
• Risks: Catalyst recycling efficiency.
• Comparisons: Surpasses prior epoxide insertions in selectivity.

Career Opportunities in Singapore Chemistry Research

Singapore's ecosystem offers postdocs, faculty roles at NUS/NTU, and industry at GSK/GSK. With 10K+ annual PhD outputs needed, skills in catalysis are prized. Explore research jobs and higher ed positions.

Photo by CDC on Unsplash